Main Menu

The live-attenuated Lassa virus vaccine, based on a recombinant Vesicular Stomatitis Virus (VSV) vector expressing the Lassa virus glycoprotein (GPC), represents a significant advancement in Lassa fever vaccination. This vaccine has demonstrated protective efficacy in animal models, showing promise for further development. Key advantages of this vaccine platform include its ability to replicate in the vaccinated individual, leading to a stronger immune response compared to non-replicating platforms.

The technology involves modifying HIV-1 envelope mosaic constructs to enhance the efficacy of HIV vaccines. These modifications target specific regions of the envelope protein, aiming to elicit antibodies similar to potent anti-HIV neutralizing antibodies naturally produced during infection. By replacing highly variable patches in the V1, V2, and V3 loops with defined sequences and eliminating immune-dominant epitopes, the modified constructs induce the production of quaternary antibodies.

The technology is a groundbreaking vaccine formulation developed through a meticulous analysis of tick salivary antigens crucial for parasitism. By examining gene expression in tick salivary glands across various life stages and comparing them with ticks feeding on naturally resistant hosts, key antigens were pinpointed. These antigens target molecules that inhibit host homeostatic responses and are predicted to be secreted toxins, making them ideal candidates for inducing immunity against tick parasitism.

This innovative technology centers on advanced peptide-based vaccine formulations that aim to significantly boost T cell-mediated immune responses. The core of this invention is the strategic conjugation of modified peptides with polymers attached to immunostimulants, a design poised to enhance the efficacy of vaccines. This approach not only promises to refine the manufacturing process, making it more efficient but also aims to augment the generation of immune responses, potentially leading to superior vaccine performance against various pathogens.

Platelet Factor 4 (CXCL4) has emerged as a promising natural inhibitor of HIV-1, offering new avenues for combating the AIDS virus. This discovery showcases CXCL4's ability to inhibit HIV-1 through a unique mechanism, primarily produced by activated platelets, which release it in high concentrations during blood clotting or inflammatory conditions. CXCL4's potential applications are diverse, ranging from therapeutic interventions to preventive measures.

The discovery involves the development of substituted phenylpyrrolecarboxamides as therapeutic agents for HIV-1 infection. These compounds target the Phe43 cavity of the HIV-1 gp120 protein, disrupting the interaction between gp120 and host cell receptors CD4 and CCR5/CXCR4, thereby inhibiting viral entry into host cells. This targeted approach presents a novel strategy for HIV therapy and prophylaxis, distinct from current treatments that target other stages of the viral life cycle.

The technology involves the discovery and development of novel compounds that inhibit the plasmodial surface anion channel (PSAC), a promising drug target for malaria treatment. These compounds have been identified through high-throughput screening as specific and potent inhibitors of PSAC, effectively killing malaria parasite cultures by blocking nutrient acquisition from human plasma. Importantly, the compounds exhibit drug-like properties and show no cytotoxicity to other cells.

This technology encompasses the discovery of broadly neutralizing antibodies against HIV-1, derived from the CAPRISA Donor CAP 256. These antibodies target the V1V2 epitope of the virus envelope and exhibit a high level of neutralization, particularly against Clade A and Clade C subtypes.

The bivalent rabies and Lassa virus vaccine represents a significant advancement in vaccine development, offering dual protection against two deadly viral diseases. By combining antigens from both viruses, this vaccine has shown promising immunogenicity in mice and efficacy in reducing viral yield in a relevant animal model.

This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).